Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PVRIG (Poliovirus receptor related immunoglobulin domain containing protein), also known as CD112R, is an immune checkpoint receptor expressed on T cells and NK cells. It binds to Nectin-2 (CD112/PVRL2) on antigen-presenting cells and tumor cells, delivering inhibitory signals that suppress T cell and NK cell activation and cytotoxicity. As such, PVRIG is a therapeutic target in cancer immunotherapy to enhance anti-tumor immunity.
PVRIG antibodies block the PVRIG/Nectin-2 interaction, preventing inhibitory signaling and enhancing T cell and NK cell activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus receptor related immunoglobulin domain containing protein (PVRIG).